Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
<p>Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor’s Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard. In the past decade, different...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2024
|
| In: |
Frontiers in immunology
Year: 2024, Jahrgang: 15, Pages: 1-13 |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2024.1350470 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2024.1350470 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1350470/full 
|
| Verfasserangaben: | Johannes Schetelig, Henning Baldauf, Falk Heidenreich, Jorinde D. Hoogenboom, Stephen R. Spellman, Alexander Kulagin, Thomas Schroeder, Henrik Sengeloev, Peter Dreger, Edouard Forcade, Jan Vydra, Eva Maria Wagner-Drouet, Goda Choi, Shankara Paneesha, Nuno A. A. Miranda, Alina Tanase, Liesbeth C. de Wreede, Vinzenz Lange, Alexander H. Schmidt, Jürgen Sauter, Joshua A. Fein, Yung-Tsi Bolon, Meilun He, Steven G. E. Marsh, Shahinaz M. Gadalla, Sophie Paczesny, Annalisa Ruggeri, Christian Chabannon and Katharina Fleischhauer for Cellular Therapy & Immunobiology Working Party of EBMT the Immunobiology Working Committee of the Center for International Blood Marrow Transplant Research (CIBMTR) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1907765514 | ||
| 003 | DE-627 | ||
| 005 | 20241205184740.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241106s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2024.1350470 |2 doi | |
| 035 | |a (DE-627)1907765514 | ||
| 035 | |a (DE-599)KXP1907765514 | ||
| 035 | |a (OCoLC)1475637506 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schetelig, Johannes |d 1968- |e VerfasserIn |0 (DE-588)120026953 |0 (DE-627)696313138 |0 (DE-576)292002831 |4 aut | |
| 245 | 1 | 0 | |a Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation |b no land in sight |c Johannes Schetelig, Henning Baldauf, Falk Heidenreich, Jorinde D. Hoogenboom, Stephen R. Spellman, Alexander Kulagin, Thomas Schroeder, Henrik Sengeloev, Peter Dreger, Edouard Forcade, Jan Vydra, Eva Maria Wagner-Drouet, Goda Choi, Shankara Paneesha, Nuno A. A. Miranda, Alina Tanase, Liesbeth C. de Wreede, Vinzenz Lange, Alexander H. Schmidt, Jürgen Sauter, Joshua A. Fein, Yung-Tsi Bolon, Meilun He, Steven G. E. Marsh, Shahinaz M. Gadalla, Sophie Paczesny, Annalisa Ruggeri, Christian Chabannon and Katharina Fleischhauer for Cellular Therapy & Immunobiology Working Party of EBMT the Immunobiology Working Committee of the Center for International Blood Marrow Transplant Research (CIBMTR) |
| 264 | 1 | |c 2024 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 2. April 2024 | ||
| 500 | |a Gesehen am 06.11.2024 | ||
| 520 | |a <p>Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor’s Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard. In the past decade, different models have been proposed aiming at maximizing NK cell activation by activating KIR-ligand interactions or minimizing inhibitory KIR-ligand interactions. Alternative classifications intended predicting outcome after alloHCT by donor KIR-haplotypes. In the present study, we aimed at validating proposed models and exploring more classification approaches. To this end, we analyzed samples stored at the Collaborative Biobank from HLA-compatible unrelated stem cell donors who had donated for patients with acute myeloid leukemia (AML) or myelodysplastic neoplasm (MDS) and whose outcome data had been reported to EBMT or CIBMTR. The donor <italic>KIR</italic> genotype was determined by high resolution amplicon-based next generation sequencing. We analyzed data from 5,017 transplants. The median patient age at alloHCT was 56 years. Patients were transplanted for AML between 2013 and 2018. Donor-recipient pairs were matched for HLA-A, -B, -C, -DRB1, and -DQB1 (79%) or had single HLA mismatches. Myeloablative conditioning was given to 56% of patients. Fifty-two percent of patients received anti-thymocyte-globulin-based graft-versus-host disease prophylaxis, 32% calcineurin-inhibitor-based prophylaxis, and 7% post-transplant cyclophosphamide-based prophylaxis. We tested several previously reported classifications in multivariable regression analyses but could not confirm outcome associations. Exploratory analyses in 1,939 patients (39%) who were transplanted from donors with homozygous centromeric (cen) or telomeric (tel) <italic>A</italic> or <italic>B</italic> motifs, showed that the donor cen <italic>B/B</italic>-tel <italic>A/A</italic> diplotype was associated with a trend to better event-free survival (HR 0.84, p=.08) and reduced risk of non-relapse mortality (NRM) (HR 0.65, p=.01). When we further dissected the contribution of B subtypes, we found that only the cen <italic>B01/B01</italic>-<italic>telA/A</italic> diplotype was associated with a reduced risk of relapse (HR 0.40, p=.04) while all subtype combinations contributed to a reduced risk of NRM. This exploratory finding has to be validated in an independent data set. In summary, the existing body of evidence is not (yet) consistent enough to recommend use of donor <italic>KIR</italic> genotype information for donor selection in routine clinical practice.</p> | ||
| 650 | 4 | |a Allogeneic hematopoietic cell transplantation (alloHCT) | |
| 650 | 4 | |a Donor Selection | |
| 650 | 4 | |a killer-cell immunoglobulin-like receptor (KIR) | |
| 650 | 4 | |a Prediction model | |
| 650 | 4 | |a risk of relapse | |
| 700 | 1 | |a Baldauf, Henning |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heidenreich, Falk |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoogenboom, Jorinde D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Spellman, Stephen R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kulagin, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schroeder, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sengeloev, Henrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Forcade, Edouard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vydra, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wagner-Drouet, Eva Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Choi, Goda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paneesha, Shankara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Miranda, Nuno A. A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tanase, Alina |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Wreede, Liesbeth C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lange, Vinzenz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmidt, Alexander H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sauter, Jürgen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fein, Joshua A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bolon, Yung-Tsi |e VerfasserIn |4 aut | |
| 700 | 1 | |a He, Meilun |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marsh, Steven G. E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gadalla, Shahinaz M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paczesny, Sophie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ruggeri, Annalisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chabannon, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fleischhauer, Katharina |d 1963- |e VerfasserIn |0 (DE-588)1246979349 |0 (DE-627)1780384173 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d Lausanne : Frontiers Media, 2010 |g 15(2024), Seite 1-13 |h Online-Ressource |w (DE-627)657998354 |w (DE-600)2606827-8 |w (DE-576)343624834 |x 1664-3224 |7 nnas |a Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation no land in sight |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g pages:1-13 |g extent:13 |a Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation no land in sight |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2024.1350470 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1350470/full |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241106 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 999 | |a KXP-PPN1907765514 |e 4610527863 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"part":{"pages":"1-13","text":"15(2024), Seite 1-13","year":"2024","extent":"13","volume":"15"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Frontiers in immunology","title_sort":"Frontiers in immunology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"issn":["1664-3224"],"zdb":["2606827-8"],"eki":["657998354"]},"language":["eng"],"origin":[{"publisher":"Frontiers Media","dateIssuedKey":"2010","publisherPlace":"Lausanne","dateIssuedDisp":"2010-"}],"pubHistory":["1.2010 -"],"recId":"657998354","note":["Gesehen am 07.11.13"],"disp":"Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation no land in sightFrontiers in immunology"}],"title":[{"title":"Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation","subtitle":"no land in sight","title_sort":"Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation"}],"person":[{"given":"Johannes","display":"Schetelig, Johannes","family":"Schetelig","role":"aut"},{"role":"aut","display":"Baldauf, Henning","family":"Baldauf","given":"Henning"},{"given":"Falk","family":"Heidenreich","display":"Heidenreich, Falk","role":"aut"},{"role":"aut","given":"Jorinde D.","display":"Hoogenboom, Jorinde D.","family":"Hoogenboom"},{"display":"Spellman, Stephen R.","family":"Spellman","given":"Stephen R.","role":"aut"},{"family":"Kulagin","display":"Kulagin, Alexander","given":"Alexander","role":"aut"},{"family":"Schroeder","display":"Schroeder, Thomas","given":"Thomas","role":"aut"},{"display":"Sengeloev, Henrik","family":"Sengeloev","given":"Henrik","role":"aut"},{"role":"aut","given":"Peter","family":"Dreger","display":"Dreger, Peter"},{"role":"aut","given":"Edouard","display":"Forcade, Edouard","family":"Forcade"},{"given":"Jan","display":"Vydra, Jan","family":"Vydra","role":"aut"},{"role":"aut","given":"Eva Maria","display":"Wagner-Drouet, Eva Maria","family":"Wagner-Drouet"},{"role":"aut","given":"Goda","family":"Choi","display":"Choi, Goda"},{"display":"Paneesha, Shankara","family":"Paneesha","given":"Shankara","role":"aut"},{"given":"Nuno A. A.","family":"Miranda","display":"Miranda, Nuno A. A.","role":"aut"},{"role":"aut","display":"Tanase, Alina","family":"Tanase","given":"Alina"},{"role":"aut","given":"Liesbeth C.","family":"de Wreede","display":"de Wreede, Liesbeth C."},{"role":"aut","given":"Vinzenz","family":"Lange","display":"Lange, Vinzenz"},{"given":"Alexander H.","family":"Schmidt","display":"Schmidt, Alexander H.","role":"aut"},{"role":"aut","display":"Sauter, Jürgen","family":"Sauter","given":"Jürgen"},{"given":"Joshua A.","family":"Fein","display":"Fein, Joshua A.","role":"aut"},{"role":"aut","given":"Yung-Tsi","family":"Bolon","display":"Bolon, Yung-Tsi"},{"role":"aut","family":"He","display":"He, Meilun","given":"Meilun"},{"family":"Marsh","display":"Marsh, Steven G. E.","given":"Steven G. E.","role":"aut"},{"family":"Gadalla","display":"Gadalla, Shahinaz M.","given":"Shahinaz M.","role":"aut"},{"given":"Sophie","family":"Paczesny","display":"Paczesny, Sophie","role":"aut"},{"role":"aut","family":"Ruggeri","display":"Ruggeri, Annalisa","given":"Annalisa"},{"family":"Chabannon","display":"Chabannon, Christian","given":"Christian","role":"aut"},{"role":"aut","given":"Katharina","display":"Fleischhauer, Katharina","family":"Fleischhauer"}],"physDesc":[{"extent":"13 S."}],"id":{"doi":["10.3389/fimmu.2024.1350470"],"eki":["1907765514"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"2024"}],"note":["Online veröffentlicht: 2. April 2024","Gesehen am 06.11.2024"],"recId":"1907765514","name":{"displayForm":["Johannes Schetelig, Henning Baldauf, Falk Heidenreich, Jorinde D. Hoogenboom, Stephen R. Spellman, Alexander Kulagin, Thomas Schroeder, Henrik Sengeloev, Peter Dreger, Edouard Forcade, Jan Vydra, Eva Maria Wagner-Drouet, Goda Choi, Shankara Paneesha, Nuno A. A. Miranda, Alina Tanase, Liesbeth C. de Wreede, Vinzenz Lange, Alexander H. Schmidt, Jürgen Sauter, Joshua A. Fein, Yung-Tsi Bolon, Meilun He, Steven G. E. Marsh, Shahinaz M. Gadalla, Sophie Paczesny, Annalisa Ruggeri, Christian Chabannon and Katharina Fleischhauer for Cellular Therapy & Immunobiology Working Party of EBMT the Immunobiology Working Committee of the Center for International Blood Marrow Transplant Research (CIBMTR)"]}} | ||
| SRT | |a SCHETELIGJDONORKIRGE2024 | ||